MEKhANIZMY DEYSTVIYa PREPARATA TsEL' T NA PATOGENETIChESKIE PROTsESSY, LEZhAShchIE V OSNOVE RAZVITIYa OSTEOARTROZA


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

This review is devoted to the analysis of the mechanisms of action of different classes of drugs on the pathogenesis of osteoarthrosis. The main advantages and disadvantages of selective and nonselective cyclooxygenase inhibitors are discussed. It is shown that, in contrast to non-steroidal anti-inflammatory drugs, the drug Zeel T has a dual mechanism of action (act both on cyclooxygenase and lipoxygenase). The review presents the results of studies confirming that such a dual inhibition allows to stop the pain and inflammation while avoiding lesions of structures of the digestive tract.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

A. Mar'yanovskiy

Әдебиет тізімі

  1. Lozada C., del Rio E., Reitberg D, Smith R., Kahn C., Moskowitz R.W. A multi-center double-blind, randomized, controlled trial (db-RCT) to evaluate the effectiveness and safety of co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections versus IA placebo in patients with moderate-to-severe pain associated with OA of the knee. Arthrit. Rheumatol. 2014; 66(suppl): S1266.
  2. Lesiak A., Gottwald R., Weiser M. Skutecznosc kuracji preparatem Zeel T w iniekcjach dostawowych okolostawowych i domiesniowych w chorobie zwyrodnieniowej stawow. Medycyna Biologiczna 2001; kwiecien czerwiec zeszyt 2: 30-36 [Effectiveness of the treatment of degenerative joint disease with periarticular, intraarticular and intramuscular injections of Zeel T. Biol. Med. 2001; 2: 30-6.
  3. Gottwald R., Weiser M. Treatment of osteoarthritis of the knee with Zeel T. Medicina Biologica. 2000; 13(4): 109-13.
  4. Wodick R.E. Steininger K., Zenner S. The biological treatment of articular affections - results of a study conducted with 498 patients. Biologische Medizin. 1993; 3: 127-35.
  5. Hieber F. Intra-articular treatment of osteoarthritis and post-traumatic arthralgia with Zeel. Fortschritte der Medizin. 1971; 89(18): 778-80
  6. Jaggi R., Würgler U., Grandjean F., Weiser M. Dual inhibition of 5-lipoxygenase /cyclooxygen-ase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability. Inflamm Res. 2004; 53(4): 150-57.
  7. Birnesser H., Stolt P. The homeopathic preparation Zeel comp. N: A review of the molecular and clinical data. Explore (NY). 2007; 3(1): 16-22.
  8. Tunon H., Olavsdotter C., Bohlin L. Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. J. Ethnopharmacol. 1995; 48: 61-76.
  9. Basini G., Santini S.E., Bussolati S., Grasselli F. Sanguinarine inhibits VEGF-induced Akt phosphorylation. Ann. N Y Acad. Sci. 2007; 1095: 371-76.
  10. Basini G., Bussolati S., Santini S.E., Grasselli F. Sanguinarine inhibits VEGF-induced angiogenesis in a fibrin gel matrix. Biofactors. 2007; 29(1): 11-8.
  11. Schmolz M. Transforming Growth Factor beta (TGF-ß): eine neue Regelstrecke für antiphlogistische Therapien? Biol. Med. 2000; 29(1): 31-4.
  12. Schmolz M., Heine H. Homöopathische Substanzen aus der antihomotoxischen Medizin modulieren die Synthese von TGF-ß 1 in menschlichen Vollblutkulturen. Biol. Med. 2001; 30(2): 61-5.
  13. Stancikova M., Bely M., Svik K., Metelmann H.W., Schmolz M.W., Istok R., Fano R. Effects of Zeel comp. on experimental osteoarthritis in rabbit knee. Rheumatologia. 1999; 13(3): 101-08.
  14. Weh L., Fröschle G. Incubation in preparations as a means of influencing cartilage mechanics: a mechanical study. Biol. Ther. 1990; 8(4): 91-3.
  15. Haseeb A., Haggi T.M. Immunopathogenesis of osteoarthritis. Clin. Immunol. 2013; 146(3): 185-96.
  16. Bonnet C.S., Walsh D.A. Osteoarthritis, angio-genesis and inflammation. Rheumatology. 2005; 44: 7-16.
  17. Malemud C.J. Anti-cytokine therapy for osteoarthritis. Drugs Aging. 2010; 27(2): 95-15.
  18. Fernadendes J.S., Materl-Pelletier J., Pelletier J.P. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002; 39(1-2): 237-46.
  19. Pearle A.D., Scanzello C.R., George S., Mandl L.A., DiCarlo E.F., Peterson M., et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage. 2007; 15(5): 516-23.
  20. Walsh D.A., Pearson C.I. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res. 2001; 3: 147-52.
  21. Mentlein R., Pufe T. New functions of angiogenic peptides in osteoarthritic cartilage. Curr. Rheumatol. Rev. 2005; 1: 37-45.
  22. Vane J.R., Botting R.M. Anti-inflammatory drugs and their mechanism of action. Inflamm. Res. 1998; 47(Suppl 2): S78-87.
  23. Park J.Y., Pillinger M.H., Abramson S.B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol. 2006; 119(3): 229-40.
  24. Giuliano F., Warner T.D. Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systems. J. Pharmacol. Exp. Ther. 2002; 303(3): 1001-06.
  25. Kawabata A. Prostaglandin E2 and painan update. Biol. Pharm. Bull. 2011; 34(8): 1170-73.
  26. Adatia A., Rainsford K.D., Kean W.F. Osteoarthritis of the knee and hip. Part I: aetiology and pathogenesis as a basis for pharmacotherapy. J. Pharm. Pharmacol. 2012; 64(5): 617-25.
  27. Pountos I., Georgouli T., Bird H., Giannoudis P. Nonsteroidal anti-inflammatory drugs: prostaglandins, indications and side-effects. IJICMR. 2011; 3: 19-27.
  28. Heller A., Koch T., Schmeck J., van Ackern K. Lipid mediators in inflammatory disorders. Drugs. 1998; 55(4): 487-96.
  29. Leone S., Ottani A., Bertolini A. Dual acting anti-inflammatory drugs. Curr. Top Med. Chem. 2007; 7(3): 265-75.
  30. Espanha M.M. [Articular cartilage: structure and histochemical composition]. Acta Reumatol. Port. 2010; 35(5): 424-33 [Article in Portuguese].
  31. Martel-Pelletier J., Boileau C., Pelletier J.P., Roughley P.J. Cartilage in normal and osteoarthritis conditions. Best Pract. Res. Clin. Rheumatol. 2008; 22(2): 351-84.
  32. Aigner T., Soeder S., Haag J. IL-1ß and BMPs -interactive players of cartilage matrix degradation and regeneration. Eur. Cell. Mater. 2006; 12: 49-56.
  33. Yasuda T., Poole A.R. A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway. Arthritis Rheum. 2002; 46: 138-48.
  34. Lozada C., del Rio E., Reitberg D.P., Smith R., Moskowiz W. Risk-benefit of co-administerd Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections in patients with moderate-to-severe pain associated with OA of the knee (OAK). Ann. Rheum. Dis. 2015; 74(Suppl. 2): Abstract THU0441.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2015

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>